↓ Skip to main content

Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)

Overview of attention for article published in American Journal of Cardiology, June 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

twitter
6 X users

Citations

dimensions_citation
61 Dimensions

Readers on

mendeley
101 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study)
Published in
American Journal of Cardiology, June 2014
DOI 10.1016/j.amjcard.2014.05.062
Pubmed ID
Authors

Alan Maisel, Yang Xue, Dirk J. van Veldhuisen, Adriaan A. Voors, Tiny Jaarsma, Peter S. Pang, Javed Butler, Bertram Pitt, Paul Clopton, Rudolf A. de Boer

Abstract

The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal pro-B-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p = 0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p = 0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal pro-B-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 2%
Spain 1 <1%
Unknown 98 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 18%
Other 10 10%
Student > Doctoral Student 9 9%
Student > Master 9 9%
Student > Bachelor 8 8%
Other 21 21%
Unknown 26 26%
Readers by discipline Count As %
Medicine and Dentistry 49 49%
Nursing and Health Professions 5 5%
Biochemistry, Genetics and Molecular Biology 5 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 3%
Veterinary Science and Veterinary Medicine 1 <1%
Other 8 8%
Unknown 30 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 November 2014.
All research outputs
#7,779,140
of 25,374,917 outputs
Outputs from American Journal of Cardiology
#3,409
of 10,182 outputs
Outputs of similar age
#70,436
of 242,775 outputs
Outputs of similar age from American Journal of Cardiology
#27
of 93 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 10,182 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 242,775 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 93 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.